Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06619093

Acronym

DREPA COAG

Enrollment

200

Registered

2024-10-01

Start date

2025-02-01

Completion date

2028-02-01

Last updated

2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease (SCD)

Keywords

Hemolysis, Coagulation, Red blood cell, Sickle cell disease

Brief summary

Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level > 484 IU/L) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.

Interventions

OTHERblood sampling

3 additional citrate tubes (2.7mL)

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

8 Years to No maximum

Healthy volunteers

Inclusion criteria

* Aged 8 years or older * Under clinical follow-up for a diagnosis of sickle cell disease, specifically genotypes S/S, S/beta0, or S/C * Patient covered by a social security or equivalent health insurance plan * Collection of the non-opposition for adults * Information of the minor and collection of the non-opposition from both parents

Exclusion criteria

* Patient who has undergone a transfusion or therapeutic phlebotomy within the 3 months prior to inclusion * Patient participating in another interventional research protocol that may interfere with the present protocol (at the investigator's discretion) * Patient under guardianship, curatorship, or legal protection * Patient subject to a legal protection measure * Person admitted to a health or social care institution for purposes other than research

Design outcomes

Primary

Measure	Time frame	Description
Overall coagulation activity	Baseline	To compare the overall coagulation activity (measurement of in vitro clot formation by rotary thromboelastometry (ROTEM)) between sickle cell patients with a severe haemolytic phenotype and those with a less severe haemolytic phenotype.

Countries

France

Contacts

Primary ContactCorine Halfon-Domenech, Dr

Carine.HALFONDOMENECH@ihope.fr0033469166550

Backup ContactPhilippe CONNES, Pr

philippe.connes@univ-lyon1.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026